ACLX241115P30000
- 0.00
- 0.000.00%
Arcellx Newsroom
Morgan Stanley Adjusts Arcellx's Price Target to $106 From $81, Keeps Overweight Rating
Arcellx Inc (ACLX) Gets a Buy From Scotiabank
A Quick Look at Today's Ratings for Arcellx(ACLX.US), With a Forecast Between $91 to $106
Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Arcellx Is Maintained at Outperform by Baird
Arcellx Analyst Ratings
Express News | Arcellx Inc : Baird Raises Target Price to $106 From $77
Acrellx Shares Are Trading Lower After the Company Announced That the Median Was Not Reached for Its Phase 1 Study of Anito-cel.
Promising Efficacy and Safety Profile of Arcellx Inc's IMMagine-1 Trial Leads to Buy Rating
Arcellx Issues Updates on Anito-cel Clinical Trials
Arcellx To Present Clinical Data for Phase 1 And IMMagine-1 Studies At 66th ASH Annual Meeting; Median Not Reached For Phase 1 Study Of Anito-cel
Stifel Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $122
Truist Financial Maintains Arcellx(ACLX.US) With Buy Rating
Arcellx (ACLX) Surged in Q3. Here's Why
CCORF Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $121
Needham Maintains Arcellx(ACLX.US) With Buy Rating, Raises Target Price to $96
Evercore Maintains Arcellx(ACLX.US) With Buy Rating, Raises Target Price to $120
Here's Why We're Not At All Concerned With Arcellx's (NASDAQ:ACLX) Cash Burn Situation
William Blair Maintains Arcellx(ACLX.US) With Buy Rating
Arcellx Inc's Anito-cel Therapy Gains 'Buy' Rating Amid Promising IMMagine-1 Study Data and Safety Profile